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ABSTRACT
In patients with ESRD, the effects of online hemodiafiltration on all-cause mortality and cardiovascular
events are unclear. In this prospective study, we randomly assigned 714 chronic hemodialysis patients to
online postdilution hemodiafiltration (n=358) or to continue low-flux hemodialysis (n=356). The primary
outcome measure was all-cause mortality. The main secondary endpoint was a composite of major car-
diovascular events, including death from cardiovascular causes, nonfatal myocardial infarction, nonfatal
stroke, therapeutic coronary intervention, therapeutic carotid intervention, vascular intervention, or am-
putation. After a mean 3.0 years of follow-up (range, 0.4–6.6 years), we did not detect a significant differ-
ence between treatment groups with regard to all-cause mortality (121 versus 127 deaths per 1000
person-years in the online hemodiafiltration and low-flux hemodialysis groups, respectively; hazard ratio,
0.95; 95% confidence interval, 0.75–1.20). The incidences of cardiovascular events were 127 and 116 per
1000 person-years, respectively (hazard ratio, 1.07; 95% confidence interval, 0.83–1.39). Receiving high-
volume hemodiafiltration during the trial associated with lower all-causemortality, a finding that persisted
after adjusting for potential confounders and dialysis facility. In conclusion, this trial did not detect a
beneficial effect of hemodiafiltration on all-cause mortality and cardiovascular events compared with
low-flux hemodialysis. On-treatment analysis suggests the possibility of a survival benefit among patients
who receive high-volume hemodiafiltration, although this subgroup finding requires confirmation.
J Am Soc Nephrol 23: 1087–1096, 2012. doi: 10.1681/ASN.2011121140
Patients undergoing chronic intermittent hemodi-
alysis have a high risk of cardiovascular morbidity
andmortality. Of the potential risk factors involved,
retention of uremic toxins in the middle molecular
mass range (0.5–40 kD) might play an important
role. During conventional hemodialysis with low-
flux membranes, low molecular mass substances
(,1.5 kD) are removed by diffusive transport,
whereas larger uremic toxins accumulate in the
body. Therefore, in the past, high-flux membranes
have been developed, which enable the removal of
larger molecules by convective transport. However,
the amount of convective transport is uncertain and
uncontrollable. Two large randomized controlled
trials did not show a distinct clinical benefit of
high-flux versus low-flux membranes.1,2
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Themagnitude of convective transport can be considerably
increased by a technique that combines high-fluxhemodialysis
with the (ultra)filtration of large amounts of plasmawater, so-
called hemodiafiltration. Obviously, fluid balance can only be
maintained if the amount of fluid withdrawn is substituted.
In the last decades, the development of sophisticated water
treatment systems and effective ultrafilters allowed the “online”
production of sterile substitution fluid at acceptable costs.With
modern online hemodiafiltration equipment, high convection
and substitution volumes can be reached safely,3 resulting
in markedly enhanced removal of middle molecular mass
substances.4–7
Several nonrandomized observational studies suggested
a survival benefit in patients who are treated with online
hemodiafiltration.8–11 However, small randomized studies
failed to show a difference between online hemodiafiltration
and standard hemodialysis (as summarized by van der Weerd
et al.12). On the basis of the above-mentioned theoretical con-
siderations, the absence of conclusive clinical data, and the
growing interest in convective techniques, the Convective
Transport Study (CONTRAST) was initiated (ClinicalTrials.
gov identifier: NCT00205556). This is a randomized controlled
trial, comparing online hemodiafiltration and low-flux hemo-
dialysis with respect to survival and various predefined second-
ary clinical endpoints.
RESULTS
Patient Characteristics at Baseline
Between June 2004 and December 2009, 714 patients (597 in
the Netherlands, 102 in Canada, and 15 in Norway) were
enrolled and randomly assigned to start online hemodiafil-
tration (n=358) or to continue low-flux hemodialysis
(n=356) (Figure 1). We achieved complete follow-up for all
participants. The two groups were well balanced with respect
to baseline characteristics (Table 1; additional information
is provided in Supplemental Table 5). A small number of
patients (6.1%) were treated with two sessions per week (26
in the hemodiafiltration group, and 18 in the hemodialysis
group).
Treatment Characteristics and Adherence
Treatment characteristics during the trial are shown in Table 2.
During follow-up, spKt/Vurea increased in patients treated
with hemodiafiltration (from 1.41 to 1.63; difference with he-
modialysis, 0.18; P,0.001). Treatment time increased from
227 to 229 minutes in the hemodialysis group and remained
stable in patients treated with hemodiafiltration (226
minutes; P=0.03 for the difference between the treatment
modalities).
As shown in Figure 2, b2-microglobulin levels decreased in
patients treatedwith hemodiafiltration (from 30.7 to 26.4mg/L)
and increased in hemodialysis patients (from 32.3 to 35.4 mg/L;
difference between treatment arms, 8.9 mg/L; P,0.001).
In patients randomized to hemodiafiltration, 2.71 (91%) of
2.99 treatments per week were actually delivered as online
hemodiafiltration during the trial. The remaining treatments
were delivered as high-flux hemodialysis. The average con-
vection volume, which includes weight loss, of all hemodiafil-
tration treatments given to participants during the entire trial
was 20.7 L/treatment session, with a median of 19.8 L.
Primary Outcome: All-Cause Mortality
After a mean follow-up of 3.04 years (range, 0.4–6.6 years;
median 2.9 years), the accumulating results met the criterion
specified by the sequential analysis plan for termination of
the study (Supplemental Figure 4). The incidence of all-
cause mortality was not affected by treatment assignment
(121 per 1000 person-years on hemodiafiltration versus
127 per 1000 person-years on low-flux he-
modialysis; hazard ratio [HR], 0.95; 95%
confidence interval [95% CI], 0.75–1.20)
(Figure 3A). Both treatment groups had
1085 person-years of follow-up.
Secondary Outcomes
The incidence of fatal and nonfatal cardio-
vascular events was 127 per 1000 person-
years in hemodiafiltration patients versus
116 per 100 person-years in patients
treated with low-flux hemodialysis (HR,
1.07; 95% CI, 0.83–1.39) (Figure 3B).
There were no significant differences be-
tween the two groups in the frequency and
incidence of individual cardiovascular
endpoints (Table 3). The incidence of re-
nal transplants was similar in both treat-
ment groups.
Figure 1. Enrollment, randomization, and follow-up of study participants. For mortality
and cardiovascular events, all patients were followed until the end of the study.
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Interactions of Treatment
Interventions with Baseline Factors
Exploratory analyses for all-causemortality
and the combined fatal and nonfatal cardio-
vascular events were performed for various
subgroups on the basis of age, sex, diabetes,
albumin #40 g/L, residual kidney function,
vascular access, and dialysis vintage.
The HRs for all-cause mortality during
treatment with hemodiafiltrationwere 0.84
(95%CI, 0.60–1.18) in patients with residual
kidney function and 1.06 (95% CI, 0.75–
1.48) in patients without. Similarly, the HRs
were not different between patients with a
dialysis vintage above and below the median
of 2.0 years (0.96 [95% CI, 0.68–1.35] and
0.91 [95% CI, 0.65–1.27], respectively).
None of the P values of the interaction terms
was significant (all.0.10).
Delivered Convection Volume and
All-Cause Mortality
Thevariation indeliveredconvectionvolumes
between participants enabled an exploration
of the achieved delivered volume of convec-
tion during the trial and clinical outcome. In
these post hoc analyses, separate models were
run with extensive adjustments for factors
that were related to the level of convection
volume achievedper session, the riskof death,
and center differences (Table 4). With respect
to all-cause mortality, a significant inverse
trend was observed (P=0.003), which re-
mained after adjustment for potential con-
founders (Table 4). In the group of patients
with the highest delivered convection vol-
ume (upper tertile .21.95 L) mortality
was considerably lower than in patients
randomized to low-flux hemodialysis
(HR, 0.62; 95% CI, 0.41–0.83). This finding
remained statistically significant after adjust-
ment for determinants of convectionvolume
and mortality (HR, 0.61; 95% CI, 0.38–
0.98). Correction for body weight and facil-
ity did not materially alter these findings. A
comparable tendency was observed for
cardiovascular events (HR, 0.72; 95% CI,
0.44–1.19), which did not reach statistical
significance (Table 4).
DISCUSSION
In this study, chronic hemodialysis patients
were randomized to treatment with online
Table 1. Characteristics of participants at baseline
Variable
Online Hemodiafiltration
(n=358)
Low-Flux Hemodialysis
(n=356)
Age (yr) 64.1614.0 64.0613.4
Female sex 144 (40) 125 (35)
Race
Caucasian 304 (85) 296 (83)
Afro-Caribbean 29 (8) 29 (8)
Asian 23 (6) 22 (6)
other 2 (1) 9 (3)
Region
Netherlands 300 (84) 297 (83)
Canada 51 (14) 51 (14)
Norway 7 (2) 8 (2)
History of cardiovascular disease 151 (42) 162 (46)
Diabetes mellitus 92 (26) 78 (22)
Dialysis vintage (yr) 2.862.9 3.062.8
median (IQR) 1.8 (1.0–3.7) 2.1 (1.0–4.0)
Systolic BP (mmHg)a 147621 148622
Diastolic BP (mmHg)a 75612 76612
Vascular access
arteriovenous fistula 279 (78) 288 (81)
graft 57 (16) 43 (12)
central catheter 22 (6) 25 (7)
Treatments/wk
3 332 (93) 338 (95)
2 26 (7) 18 (5)
Duration of a dialysis session (min) 226626 227622
Blood flow (ml/min) 302639 299641
Dialysis single-pool Kt/Vurea 1.4160.24 1.3860.19
Residual kidney functionb 186 (52) 190 (53)
Estimated GFR
ml/min per 1.73m2c 2.163.4 2.063.3
median (IQR) 0.32 (0–3.30) 0.30 (0–3.35)
Hemoglobin (g/dl) 11.961.3 11.861.2
Phosphorus (mg/dl) 5.1261.58 5.0561.46
b-2-microglobulin (mg/L) 30.7614.3 32.3613.6
SGA classification
well nourished 290 (81) 297 (83)
mild to moderate malnutrition 68 (19) 58 (16)
severe malnutrition 0 (0) 1 (0)
BMI after dialysis (kg/m2) 25.265.0 25.664.6
Albumin (g/L) 40.263.8 40.663.9
C-reactive protein (mg/L) 10.9 (20.2) 10.2 (26.3)
median (IQR) 4.1 (1.4–10.7) 3.9 (1.3–10.2)
Creatinine (mg/dl), predialysis 9.5262.94 9.9462.83
Cholesterol (mg/dl) 142635 142641
Prescribed medication
b blocker 184 (51) 193 (55)
RAS inhibitor 179 (50) 170 (48)
platelet aggregation inhibitor 111 (34) 127 (36)
1-OH and 1,25-OH vitamin D 227 (63) 254 (72)
statin 198 (55) 164 (46)
erythropoiesis stimulating agents 314 (88) 319 (90)
Dataarepresentedasn (%)ormean6SD.SGA, subjectiveglobal assessment; RAS, renin-angiotensin system.
aBefore hemodialysis.
bResidual kidney function if diuresis .100 ml/24 h.
cMean of urea and creatinine clearance in 24-hour urine collection; mean plasma creatinine and urea
concentrations during the collection period were estimated using the geometric mean of postdialysis
and predialysis plasma samples.
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postdilution hemodiafiltration or to continuation of low-flux
hemodialysis.After amean follow-upof3.04 years, treatmentwith
hemodiafiltration did not result in lower all-cause mortality nor
did it have a beneficial effect on the composite endpoint of
fatal and nonfatal cardiovascular events.
This study is the first large-scale, ran-
domized prospective trial designed to com-
pare online hemodiafiltrationwith low-flux
hemodialysis. Two earlier large randomized
studies addressed the hypothesis that re-
moval of larger uremic toxins would improve
survival probability. Both the Hemodialysis
(HEMO) study and the Membrane Perme-
ability Outcome (MPO) study compared
low-flux hemodialysis with high-flux hemo-
dialysis.1,2 Neither study showed a difference
inmortality risk between the treatment arms.
Convective transport, as quantified by a
decrease in b-2-microglobulin levels, is
higher during hemodiafiltration than dur-
ing high-flux hemodialysis and is negligible
during low-flux hemodialysis. In our study,
the predialysis b-2-microglobulin levels in
the hemodiafiltration group were consis-
tently lower than those in hemodialysis pa-
tients. The difference in this study was
more than twice the difference between
the high-flux and low-flux arms achieved
in the MPO study.2 Nonetheless, the main
outcome of our study does not deviate
from the results of both the HEMO and
MPO studies. Therefore, it seems that the
addition of convective transport does not
improve survival in chronic dialysis pa-
tients, at least not when the average delivered convection vol-
ume over time is #20.7 L/treatment.
Secondary analyses in the HEMO and MPO studies sug-
gested a survival benefit of high-flux hemodialysis in patients
with a dialysis vintage.3.7 years,13 patients with diabetes, and
Table 2. Mean characteristics of treatment during follow-up
Characteristic
Online
Hemodiafiltration
Low-Flux
Hemodialysis
Mean Difference
(SEM)
P Value for
Difference
Duration of dialysis session (h) 3.77 (0.01) 3.81 (0.01) 20.04 (0.02) 0.02
Blood flow (ml/min) 332 (2.6) 312 (2.3) 20 (3.4) 0.001
Sessions/wk (n) 2.99 (SD 0.6) 2.99 (SD 0.7) 0.002 (0.02) 0.25
Online hemodiafiltration
number of sessions/wka 2.71 (SD 0.35) NA
convection volume (L)/treatment 20.7 (SD 6.0) NA
Single-pool Kt/Vurea 1.63 (0.02) 1.45 (0.02) 0.18 (0.03) ,0.001
b-2-microglobulin (mg/L) 26.4 (0.37) 35.4 (0.54) 28.9 (0.7) ,0.001
Albumin (g/L) 39.4 (0.14) 39.7 (0.15) 20.30 (0.20) 0.14
CRP (mg/L) 11.9 (1.4) 11.4 (1.2) 0.52 (1.9) 0.77
Hemoglobin (g/dl) 11.8 (0.03) 11.6 (0.03) 0.11 (0.05) 0.03
Phosphorus (mg/dl) 4.80 (0.06) 4.95 (0.06) 0.19 (0.06) 0.02
Cholesterol (mg/dl) 143 (2) 139 (2) 2 (2) 0.28
Predialysis systolic pressure (mmHg) 146 (1) 145 (1) 0.9 (0.5) 0.49
Interdialytic weight change, pre 2 post (kg) 1.91 (0.05) 1.85 (0.05) 0.05 (0.07) 0.51
Average levels during the trial and mean difference over time between treatment arms obtained through GEE analyses using the on trial measurements with
adjustments for baseline measurements. Values are means (SEM) unless otherwise indicated. NA, not applicable; CRP, C-reactive protein.
aActual number of sessions per week delivered as online hemodiafiltration during the trial, the other sessions were delivered as high-flux hemodialysis.
Figure 2. Predialysis b-2-microglobulin levels in patients treated with online hemo-
diafiltration and low-flux hemodialysis (mean 6 SEM) using measurements of individuals
at those time points. The difference between b-2-microglobulin levels for both treat-
ments was significant (P,0.001).
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patients with a serum albumin #40 g/L at baseline.2 In our
study, neither dialysis vintage nor albumin levels or the pres-
ence of diabetes affected the direction and magnitude of the
relation between hemodiafiltration and outcome. In a previous
analysis of the CONTRASTstudy, we showed that the effect of
online hemodiafiltration on b-2-microglobulin levels was es-
pecially present in patients without residual kidney function.7
However, neither residual kidney function, nor an analysis of
other predefined subgroups, such as primary kidney disease,
age, co-morbidity, and sex modified the effect of treatment
in our study. Because the CONTRAST study was not pow-
ered to detect differences between low-flux hemodialysis
and hemodiafiltration on outcome across subgroups, our
“null” results in subgroup analyses do no exclude the pres-
ence of such a relation.
The lack of an overall beneficial effect of hemodiafiltration
on survival might be explained by several factors. First, the
positive effect of an increased removal of uremic toxins might
be counteracted by the simultaneous loss of essential substan-
ces,14 and/or undesirable side effects of the treatment itself.15
Second, although the Kaplan–Meier curves did not even
show a trend for a better outcome, the intervention period
(mean 3.04 years) may have been too short for an effect on
survival. Third, the positive effect of hemodiafiltration observed
in observational studies might be due to the utilization of ultra-
pure dialysis fluids, which is mandatory for this treatment. The
application of contaminated dialysis fluids during conventional
hemodialysis might negatively influence patient health.16 In our
study, ultrapure dialysis fluid was used in both treatment arms.
Finally, because the actual convection volume per session
(20.7 L/treatment) was below the arbitrary planned target of
24 L/treatment (6 L/h), and 9% of hemodiafiltration treatments
were delivered as high-flux hemodialysis, the average amount of
convective transport actually delivered to the participants during
the studymight have been too low toobtain an effect onoutcome.
We thus explored the relation between delivered convection
volume and mortality. Our post hoc analysis showed a significant
inverse relation between delivered convection volume and mor-
tality risk (P=0.010). Despite extensive adjustments for potential
confounders, the HR for all-cause mortality was considerably
lower in the group of patients treated with the highest delivered
convection volumes (.21.95 L; HR, 0.62; 95% CI, 0.38–0.98),
whereas a nonsignificant trend was observed for fatal and non-
fatal cardiovascular events (HR, 0.72; 95% CI, 0.44–1.19). Al-
though the finding of an association between convection dose
and outcome is conceptually plausible and in agreement with
observational data from the Dialysis Outcomes and Practices
Pattern Study (DOPPS),8 this finding requires further inves-
tigation and confirmation. A survival benefit was observed in
DOPPS patients with a substitution volume .15 L/session,
which did not include net ultrafiltration (i.e., desired weight
loss).8 Data from the Turkish Hemodiafiltration Study, a ran-
domized trial comparing high-flux hemodialysis with online
hemodiafiltration, show that the overall outcome was not af-
fected by treatment allocation, whereas high convectionvolumes
were associatedwith a significant survival benefit (48thCongress
of the European Renal Association-European Dialysis Trans-
plant Association, 2011, abstract LBCT2).
Whenour studywas designed, a target convectionvolumeof
24 L/treatment was merely based on themanufacturer’s guide-
lines and considered the maximum achievable dose in daily
practice during one single treatment. Data linking convection
volume to clinical outcome were lacking at that time. The
finding that the target volumewas not achieved in themajority
of patients is a reflection of common practice and as such an
important finding. In a previous analysis of the CONTRAST
study, we showed that both the blood flow rate through the
Figure 3. The incidence of both all-cause mortality and cardio-
vascular events was not affected by treatment assignment. Sur-
vival curves for time to death from any cause (A) and for time to
fatal or nonfatal cardiovascular event (B) based on life table
analyses using 3-month time periods.
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extracorporeal circuit and treatment time are potentially
modifiable determinants of convection volume.17,18
Apart from survival, other endpointsmight be of relevance.
Itwas recently shown that the applicationof convective therapy
was associated with better intradialytic hemodynamic stabil-
ity.19 Other aspects, such as quality of life, erythropoietin re-
sistance, vascular stiffness, left ventricular mass, nutritional
status, and cost utility, are currently under investigation as
predefined secondary endpoints of this study.20,21
The strengths of our study are its randomized design and the
accurate and concise data collection. The external validity of
our study is supportedby the fact that the variables age, sex, and
primary kidneydisease of our patients are similar to those in all
Dutch patients registered in the RENINE database (www.
renine.nl). Because this trial was event driven, the number
of events was sufficient for adequate and valid conclusions. In
other words, a small sample size does not explain our null find-
ing. A potential limitation may be the inclusion of prevalent
patients (as being survivors), as illustrated by a mean dialysis
vintage of 2.9 years. Whether the inclusion of incident patients
would have resulted in a different outcome cannot be con-
cluded from this study, although the interaction analysis did
not show differences in results between patients with a low
and a high dialysis vintage.
Recent guidelines advocate high-fluxhemodialysis asfirst-line
treatment.22 The fact thatwedidnotfind a difference in outcome
between low-flux hemodialysis and hemodiafiltration suggests
that comparison of high-flux hemodialysis with hemodiafiltra-
tion is even less likely to result in a difference in outcome.
Finally, because the relation between all-cause mortality and
convection volume was found in an on-treatment analysis, this
result shouldbe interpretedwithcautionandneedsconfirmation.
In conclusion, our study showed that treatment with online
hemodiafiltration did not result in a reduced mortality or less
fatal and nonfatal cardiovascular events compared with
treatment with low-flux hemodialysis. Subgroup analysis did
Table 3. Primary and secondary outcomes
Outcome
Online Hemodiafiltration Low-Flux Hemodialysis
HR (95% CI)aNumber
of Events
Person-Years
of Follow-Up
Number
of Events
Person-Years
of Follow-Up
Primary outcome
all-cause mortality 131 1085 138 1085 0.95 (0.75–1.20)
Main secondary outcomes
fatal and nonfatal cardiovascular events 116 916 112 964 1.07 (0.83–1.39)
cardiovascular mortality 37 1085 46 1085 0.80 (0.52–1.24)
nonfatal cardiovascular disease (first event) 94 915 87 964 1.12 (0.83–1.49)
fatal and nonfatal CHD (MI, PTCA, CABG) 38 1000 47 1022 0.81 (0.52–1.23)
fatal and nonfatal stroke 19 1066 16 1062 1.17 (0.60–2.27)
amputation 21 1058 16 1068 1.31 (0.68–2.51)
sudden death 21 1085 21 1085 1.00 (0.55–1.83)
vascular intervention 59 978 49 1010 1.23 (0.84–1.79)
transplantation 78 800 73 798 1.06 (0.77–1.46)
hospital admissions due to infection 130 800 110 798 1.21 (0.94–1.56)
CHD, coronary heart disease; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft.
aObtained through unadjusted Cox proportional hazards models.
Table 4. Risk of all-cause mortality and fatal and nonfatal cardiovascular events by achieved convection volume in
liters per treatment
Hemodialysis
Online Hemodiafiltration Convection Volume Tertiles
P for Trend
,18.17 L 18.18–21.95 L >21.95 L
Total mortality
crude 1.0 0.95 (0.66–1.38) 0.83 (0.57–1.22) 0.62 (0.41–0.93) 0.010
adjusteda 1.0 0.79 (0.53–1.14) 0.77 (0.51–1.14) 0.65 (0.42–0.99) 0.012
adjustedb 1.0 0.80 (0.52–1.24) 0.84 (0.54–1.29) 0.61 (0.38–0.98) 0.015
Fatal and nonfatal cardiovascular events
crude 1.0 1.37 (0.94–1.98) 1.06 (0.72–1.56) 0.76 (0.50–1.16) 0.473
adjusteda 1.0 1.41 (0.92–2.11) 0.93 (0.62–1.40) 0.77 (0.48–1.21) 0.369
adjustedb 1.0 1.35 (0.86–2.11) 1.04 (0.66–1.62) 0.72 (0.44–1.19) 0.475
Results reported as HR and 95% confidence interval, from Cox proportional hazards models. Reference is treatment with low-flux hemodialysis.
aAdjusted for determinants of mortality, i.e., age, sex, previous vascular disease, diabetes, previous transplantation, spKt/V, baseline eGFR, baseline albumin,
baseline creatinine, baseline hematocrit, and use of a- and b-blockers, calcium antagonists, and angiotensin converting inhibitors at baseline (82 missing, 206
deaths, 182 cardiovascular events).
bAdjusted for the above-mentioned determinates as well as for center differences (82 missing, 206 deaths, 182 cardiovascular events).
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not yield a benefit of hemodiafiltration over hemodialysis in
patients with diabetes, cardiovascular disease, long dialysis
vintage, low albumin, or lack of residual kidney function. On-
treatment analysis suggests a survival advantage in patients
receiving the highest convection volumes. These data must be
confirmed by other studies in progress23,24 and/or by a meta-
analysis of individual patient records from controlled clinical
trials on this topic.
CONCISE METHODS
Study Design
CONTRAST is a randomized controlled trial conducted in twenty-
nine dialysis centers: the Netherlands (n=26), Canada (n=2), and
Norway (n=1). This study was performed in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines and
was approved by both a central medical ethics review board and local
ethics committees. Written informed consent was obtained from all
patients before enrollment. Detailed study methods were previously
published.25
CONTRAST is an investigator-initiated trial that was designed,
conducted, and analyzed independently of the financial contributors.
Study data were collected and retained by the investigators and were
not available for the financial contributors. The writing executive
committee, whose membership did not include representatives of the
financial contributors, hasfinal responsibility for the interpretation of
thedata, the preparationof themanuscript, and thedecision to submit
for publication. The executive committee vouches for the validity and
completeness of the reported data.
Patients
Patients with ESRD undergoing chronic intermittent hemodialysis for at
least 2 months and aged $18 years were recruited from June 2004
throughDecember 2009 and followed until December 31, 2010. Primary
renal diagnoses were as follows: renal vascular disease (29%), diabetes
mellitus (19%), primary glomerulopathy/GN (12%), interstitial ne-
phropathy (9%), cystic kidney disease (7%), multisystem disease (4%),
other (12%), or unknown(8%). Patientswere eligible for inclusion if they
were treated two or three times per week with low-flux hemodialysis.
Exclusion criteria were as follows: treatment with hemo(dia)filtration or
high-flux hemodialysis in the 6 months preceding randomization, a life
expectancy,3months due to nonrenal disease, participation in another
clinical intervention trial evaluating cardiovascular outcomes, and severe
nonadherence regarding frequency and/or duration of dialysis treatment.
Randomization and Blinding
All patients were randomized centrally by a computer-based ran-
domization service (JuliusCenterUniversityMedical Center,Utrecht,
The Netherlands) into a 1:1 ratio for treatment with online hemo-
diafiltration or continuation of low-flux hemodialysis, stratified per
participating center (permuted blocks). Because of the nature of the
intervention, it was not possible to blind the patients, the local
study nurses, or the investigators to the treatment assignment. The
laboratory samples were measured in routine clinical care; hence,
personnel were unaware of treatment assignment. The event adjudi-
cation committee was blinded to the treatment assignment.
Treatment and Procedures
Before randomization, all patients had to be stable with a minimum
dialysis single-pool Kt/V for urea (spKt/Vurea) of 1.2. Treatment times
were fixed during follow-up in both treatment arms, unless spKt/
Vurea was ,1.2.
Online hemodiafiltration was performed in the postdilution
modewith a proposed target convectionvolume of 6 L/h, whichwas
based on a targeted filtration rate between 25% and 33% of an
extracorporeal blood flow rate between 300 and 400 ml/min (so-
called filtration fraction). Blood flow rates could be increased in the
hemodiafiltration arm to improve convection volumes. Because
evidence relating convection volume and outcome was absent at the
time of the start of the study, the proposed target was arbitrarily based
on the level considered themaximal achievable convection volume in
the postdilution mode.
Synthetic high-flux dialyzers were used for hemodiafiltration
(ultrafiltration coefficient [KUF] .20 ml/mmHg per h; FX80: 27%,
FX100: 11%, andOptiflux F200NR: 8% [FreseniusMedical Care, Bad
Homburg, Germany]; Polyflux 170H: 25% and Polyflux 210H: 27%
[Gambro AB, Stockholm, Sweden]; or other dialyzers: 2%). Hemo-
dialysis patients were treated with synthetic low-flux dialyzers
(KUF,20 ml/mmHg per h; F6HPS: 5%, F8HPS: 45%, and Optiflux
18NR: 9% [Fresenius]; Polyflux 14L: 2% and Polyflux 17L: 30%
[Gambro], or other: 9%). More detailed information on dialyzer
characteristics is provided in Supplemental Table 6. When hemo-
diafiltration could temporarily not be performed due to technical
reasons, the patients concerned were treated with high-flux mem-
branes. Both hemodiafiltration and hemodialysis were performed
with ultrapure dialysis fluids, defined as,0.1 colony forming units
per milliliter and ,0.03 endotoxin units per milliliter. In a subset
of the participating centers, 99% of the samples were within refer-
ence quality levels.26 Routine patient care was performed according
to national and international quality of care guidelines.
At baseline, informationondemography, historyof cardiovascular
disease, diabetes mellitus, medication, type of vascular access, and
duration of dialysis (dialysis vintage) was assessed. At each quarterly
visit, information on clinical events, dialysis treatment, medication,
and laboratory values was recorded. History of cardiovascular disease
was defined as a confirmative answer on any of the questions re-
gardingaprevious acutemyocardial infarction, coronary arterybypass
graft, percutaneous transluminal coronary angioplasty, angina pec-
toris, stroke, transient ischemic attack, intermittent claudication,
amputation, percutaneous transluminal angioplasty, peripheral by-
pass surgery, and renal percutaneous transluminal coronary angio-
plasty. In addition, bloodflow rate, intradialyticweight loss, treatment
time, infusion volume, and predialysis BP were assessed. In hemo-
diafiltration patients, infusion volumes (liters per treatment) were
reported as the mean value of three consecutive treatment sessions
preceding the quarterly visit. Convection volumes (liters per treat-
ment) were calculated as the sum of the intradialytic weight loss and
the substitution volume per session. For calculation of the convection
volume in the on-treatment analysis, at every quarterly visit, the actual
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number of hemodiafiltration treatments in the past 3 months was
assessed. Patients couldmiss hemodiafiltration treatments (and then be
treated with high-flux hemodialysis) due to technical problemswith the
water installation or vacation schedules. Themean delivered convection
volume during the trial was estimatedwith the following formula:mean
delivered convection volume = (hemodiafiltration treatments/total
number of treatments) 3 mean convection volume of the three treat-
ments preceding the quarterly visit.
Every 3months, blood sampleswere drawnbefore dialysis (the day
was chosen according to local schemes), and when appropriate, after
the session. Serum b-2-microglobulin (molecular mass of 11.8 kD)
was assessed at baseline and every 6 months thereafter. All samples
were analyzed in the local laboratories of the participating hospitals
by standard laboratory techniques. Interdialytic urinary samples were
collected during each quarterly visit in patients with a urinary pro-
duction $100 ml/d. In these patients, residual kidney function was
expressed as the estimated GFR (eGFR), calculated by the mean of
24-hour urinary creatinine and urea clearances and adjusted for body
surface area (milliliters per minute per 1.73 m2). The plasma concen-
trations used for this calculation were the mean of the values before
and after dialysis. The eGFR was considered zero in patients with a
urinary production ,100 ml/d. Dialysis adequacy was expressed as
spKt/Vurea, calculated with the second-generation Daugirdas for-
mula.27
Outcomes
The primary study outcome was all-cause mortality. Deaths were
reported within 24 hours to the data management center by fax or
email. The main secondary endpoint was a composite of fatal and
nonfatal cardiovascular events. Cardiovascular events were defined as
death from cardiovascular causes, nonfatal myocardial infarction,
nonfatal stroke, therapeutic coronary procedure (coronary artery
bypass graft, percutaneous transluminal coronary angioplasty, and/or
stenting), therapeutic carotid procedure (endarterectomy and/or
stenting), and vascular intervention (revascularization, percutaneous
transluminal angioplasty, and/or stenting), or amputation. Conges-
tive heart failure was not considered as a cardiovascular event and
hencewas not formally evaluatedby the event adjudication committee
because the distinctionwith fluid overload is often difficult tomake in
patientswithESRD.Hospitalizations, durationof thehospitalizations,
and main diagnosis (including infections) were recorded during the
study period.
After participants stopped randomized treatment due to renal
transplant (n=151), switch to peritoneal dialysis (n=11), move to
another (non-CONTRAST) hospital (n=24), or other reasons
(n=53), they continued to be followed for the primary and main
secondary outcome, being death and (non)fatal cardiovascular
events. These patients were not followed for the occurrence of non-
cardiovascular events such as hospitalization due to infection.
Interim Analyses and Data Monitoring
An independent endpoint adjudication committee, whose members
were not aware of the treatment assignments, reviewed source
documentation for all primary outcome events (deaths), as well as
nonfatal cardiovascular events and infections.
A separate, independent data and safety monitoring board,
evaluated the results of sequential interim analyses. Every 2 months,
sequential unblinded analyses were performed on the cumulative
database. On the basis of this design, the board decided whether the
data provided enough evidence of either efficacy or futility with
respect to the primary outcome and sufficient support to formulate
recommendations for the executive committee to continue the trial.
Guidelines for early discontinuation were previously published.25 In
December 2010, the board recommended to stop the trial because
enough evidence was provided for futility (i.e., no clear efficacy of he-
modiafiltration over hemodialysis).
Statistical Analyses
The CONTRASTstudy was designed to have 80% statistical power to
detect a relative risk reduction of$20% for online hemodiafiltration
compared with low-flux hemodialysis for the primary outcome,
with a two-sided a level of 5%. A 3-year incidence of death from
any cause of 44% was expected in hemodialysis patients and a relative
risk reduction of$20% by hemodiafiltration was assumed. The pri-
mary outcome was time to death, and a relative risk reduction was
translated to a HR of 0.75, which is equal to the ratio of the logarithm
of the expected cumulative survival proportion under hemodiafiltra-
tion (1 – 0.352 = 0.648) and the logarithm of the expected cumulative
survival proportion under hemodialysis (1 – 0.44 = 0.56). For a se-
quential design, no fixed sample size estimate can be provided. Ap-
proximately 772 patients needed to be enrolled and followed for
about 3 years. To reach a decision, approximately 250 endpoints
were expected in these patients. A double sequential triangular test
as proposed by Whitehead28 was used to monitor accumulating data
and to test the primary hypothesis.
Several analyses were performed. First, all primary analyses were
conducted according to the intention-to-treat principle. Data for
patientswere censored at their date of death, date of last visit (for those
still alive at the end of the follow-up at December 31, 2010), or date
when last known to be alive (for those with unknownvital status). The
primary endpoint was analyzed cumulatively by sequential analysis28
using the PEST program (version 4.4).29 Point and interval estimates
were adjusted for cumulative testing. Effects of treatment on second-
ary study endpoints were estimated with the use of unadjusted Cox
proportional hazards models, involving the time to the first relevant
endpoint in any individual patient. Second, homogeneity of treat-
ment effects across subgroups was tested by adding interaction terms
to the relevant Cox models. Third, to study differences in continuous
and dichotomous variables between the two treatment arms during
the follow-up period, we applied linear mixed models (generalized
estimating equation [GEE]). The main assumption of the GEE ap-
proach is that measurements are assumed to be dependent within
participants and independent between participants. The correlation
matrix representing the within-patient dependencies was estimated
using an autoregressive relationship.30 For these analyses, the interest
was in the mean difference over time in risk factor levels between
treatment arms. GEE analyses were performed using the on-trial
measurements adjusted for the level of the variable of interest at
baseline. Finally, based on the existing literature, we explored
whether the treatment effect depended on the average amount of
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convection volume that was delivered to the hemodiafiltration pa-
tients during the trial. For this purpose, the actual (on-treatment)
delivered convection volume was divided in tertiles, which were in-
troduced in a Cox proportional hazards model as dummy variables.
Patients who were treated by low-flux hemodialysis served as the
reference group (no convection volume). In this post hoc analysis,
elaborate adjustments were made for factors that have previously
been related to convection volume (age, sex, albumin, and hemato-
crit),18 and for potential determinants of mortality. Furthermore, to
account for potential differences between study facilities, center ad-
justments were made.
All P values were two sided, and P values ,0.05 were considered
significant. No adjustment for multiple statistical testing was made.31
Analyseswere performedwith SPSS 17 software (SPSS Inc,Chicago, IL).
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